




entrinsic health solutions

*Disruptive Amino Acid
Technology Platform*



Discovery, development and commercialization of disruptive consumer health products

- ✓ **Broad, disruptive, technology platform based on targeting and restoring key protein functions altered in organ systems during disease states**
 - Unique, patented combinations of small molecule formulations addressing multiple drivers of healthy metabolic function or dysregulation for use in either consumer health or drug applications
- ✓ **Faster commercialization model**
 - Non – IND Clinical, IRB approved studies for faster proof of principle and accelerating lead candidates to pivotal trials
 - Multiple Regulatory Pathways
 - Medical Food, OTC, Drug
- ✓ **Experienced team and advisory board**
 - Commercially launched proof of principle product into oncology market attracted key strategic Partner (NHSc)
- ✓ **Proven business model for new product roll out's with other key strategic partner**
- ✓ **Investments only in key value driver: develop and deliver proof of principle product to attract strategic partners**
 - Exit strategy developed





Science Behind the Technology

Targeting and Restoring Key Protein Functions Altered in Organ Systems during Disease States:


- Dr. Sadasivan Vidyasagar's world-leading scientific research on the use of targeted amino acid combinations to correct primary functional alterations common to various diseases, illness and metabolic dysregulations.
- Scientifically derived combinations of select amino acids (based on key targets or specific activity) offers measurable improvement in primary cellular mechanisms throughout the body
- Robust data provided by 19 Published Studies and Clinical Trials

Metabolic and Physiological dysregulation is at the heart of many diseases and achieving peak physiological function is core to health and wellness.





Disruptive A₂CT Technology Platform





Strong Intellectual Property Position

Broad Rights to Select Amino Acids with Unique Properties

▪ **Portfolio Status**

- 5 key Patent Families leading to 22 Issued patents and 52 Pending/Published Patents
- University of Florida Research Foundation has been granted a patent on a composition comprising a combination of up to 9 amino acids that does not have glucose, methionine or glutamine (*Granted patent: US8993522 B2 | Issue date: 03-31-2015*)

▪ **Materials and methods for improving Gastrointestinal function (*US8993522 | Granted*)**

- The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa

▪ **Materials and methods for treatment of Cystic Fibrosis and for induction of ion secretion (*WO2013151744 | Application*)**

- The present invention provides materials and methods for inducing ion secretion and/or for treating cystic fibrosis

▪ **Materials and methods for treating diarrhea (*US20140377374 | Application*)**

- The present invention provides therapeutic compositions and methods for treating gastrointestinal diseases and conditions such as diarrhea, for providing rehydration, for correcting electrolyte and fluid imbalances, and/or for improving small intestine function

▪ **Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications (*US20160015664 | Application*)**

- The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function

▪ **Other pending applications**

- Amino acid compositions for the treatment of symptoms of disease
- Amino acid compositions and uses thereof. A method for treating a disease or condition that is related to mucosal barrier function

EHS A₂CT Technology Platform – *A Proven Result*

Opening up opportunities to build significant, sustainable Consumer Health and other businesses across multiple market verticals.

- Commercial Validation: enterade® an early clinical success and commercial roll -out in oncology market addressing unmet needs in hydration and diarrhea



- Broad applicability: Addresses multiple disease states through functional alterations of key proteins
- Proprietary and patented technology, with all natural properties
- Business strategy: Rapid development, clinical confirmation (IRB) and commercialization with high value strategic/ technology fits through respected strategic multinationals
- Strategic partnerships Potential: Leaders in medical, consumer/lifestyle, nutrition and animal health



- Target addressable markets with over \$100B potential market opportunity



Putting the Technology to the Test



VALIDATION

- Delivers total hydration, cellular regeneration and strengthened barrier function
- Highly customizable transport system to address multiple target conditions and diseases
- Data supports MOA, efficacy and safety

enterade® - Successful Oncology Solution

Successful launch of flagship product, enterade®, a proprietary, patented, natural amino acid solution

In Q4 2016, after establishing the efficacy and safety of enterade®, EHS launched enterade® Advanced Oncology Formula, which focuses on the GI side effects of cancer treatment.

Oncology market launch tactics:

- Educate healthcare providers and drive patient awareness and trial
- Expand salesforce in Q2 2017
- DTC promotion to patients online, and gain Advocacy support
- eCommerce established through Amazon and enterade.com

Successfully monetized global partnership with nutrition leader in Nestlé

- Reaffirmed clinical efficacy of enterade®
- Proved commercial viability of enterade®
- Successfully monetized global partnership with nutrition leader in Nestlé





Disruptive Development & Business Models

Rapidly building a robust pipeline of A₂CT candidates through an innovative approach that integrates preclinical and human signal seeking and confirming studies to understand the impact of specific combinations on human biology.

This fast and capital efficient, iterative process has the potential to generate drug or consumer health product candidates with a higher probability of success in the development process.

- Stage gate
- Proof of concept
- Clinical validation

Proprietary, patented specialized formulations to target specific health opportunities and/or disease states


- Unique
- Specific
- Regulatory

Pre-IND, IRB approved studies evaluate safety and tolerability of A₂CT candidates in human subjects, or effects on normal structure or function of the body. Studies intended to support drug development will be conducted under and IND



Strategic Focus – Gut Health

EHS is immediately focused on realizing a commercial return on gut health opportunities...



Medical Food/ OTC Products	
Oncology	
Medical Hydration	
Anti-Diarrheal Hydration Iron Absorption Constipation	

Nestlé
HealthScience
Signed partnership Q4 2018



Strategic Plan 2019-2022

- Seeking up to \$25 million Series C to fund pipeline and program acceleration
- Position for a strong exit(s) post 2022 timeframe

Advance select pipeline programs

Establish proof of principle expectations to potential strategic partner(s)

Monetize Programs & Product Concepts

Target relevant strategic partners after proof of principle

Position Programs to maximize shareholder value

Establish strategic partner plans, rationale, and strategic drivers for each Program

Invest in proprietary R&D


Accelerate the pipeline platform and protect knowledge, build EHS IP

Maximize Value from Current/Pending Programs





Market Opportunities to Deliver “Proof of Principles”





Identified Strategic Partners

PLATFORM TARGET	TRANSLATIONAL THERAPEUTICS	MEDICAL FOOD / OTC PRODUCTS	CONSUMER HEALTH FOOD (FDCG)
<p>GI Health Market Size US \$12B</p>	 Abbott <i>Baxter</i> 	 Abbott <i>Baxter</i>   DANONE  Nestlé <small>ONE PLANET. ONE HEALTH HealthScience</small>	  <small>Unilever</small>
<p>Respiratory Health Market Size US \$4.8B</p>	 NOVARTIS  	 	
<p>Skin Care / Personal Care Market Size US \$46B</p>	 NOVARTIS  <i>Johnson & Johnson</i>	<i>Johnson & Johnson</i>   <small>Unilever</small>	
<p>Platform and R&D growth engine</p>	   DSM <small>BRIGHT SCIENCE. BRIGHTER LIVING.</small> 		



Potential Shareholder Value at Time of Exit

Oncology & G.I. Care

- Nestle Health Sciences – Global Commercial Partnership
- Deal Value: \$100 million
- Target Addressable Market : \$700+ Million

G.I. Health

- Total Addressable Market: \$12B
- Potential Deal Value: \$ 150 – 250 million

Pulmonary Health

- Total Addressable Market: \$4.8B
- Potential Deal Value: \$ 200 - 300 million

Skin Care / Personal Care

- Total Addressable Market: \$46B
- Potential Deal Value: \$ 300-400 million

Additional Option Value from Early Pipeline

- Advance POC with pre-clinical and pilot clinical data on high value targets
- e.g. Iron Metabolism, Constipation

Enhanced Perpetuity Value

- Monetizing terminal Value of Technology Platform(s) to Strategic Partner(s), including Ingredient Player(s)



US \$25 Million Capital Raise

Use of Funds 2019-2021

Invest in Core Value Drivers – *Strategic Actions for 2019*

PEOPLE

- Organizational Buildout with Key Hires: Financial, R&D, Business Development
- Invest and Fund EHS R&D Laboratories to expand research capabilities beyond Univ. of FLA

GLOBAL PARTNERSHIPS

- Business Development to establish EHS Strategic Plans and Strong Value Propositions for Global Partnerships
- Define Develop Targeted Product Concepts including Pre-clinical Data and the conduct of key Clinical Trials for establishing solid Proof of Principles
- Progress Global Partnership with NHSc

PRODUCTS & PIPELINE

- Continue to build out strong Patent Portfolio
- Finalize Medical Hydration Concept and Positioning
- Advance Pulmonary – Allergy and Rhinitis product concepts
- Advance Skin Formulation Development
- Initiate Anti-Diarrheal Pivotal Clinical Trial



Entrinsic Health:

Moving Innovative Science to Commercial Return Quickly & Effectively



Disruptive Platform

- Proprietary and patented amino acid science has been validated through several preclinical and clinical studies that demonstrate the unique mechanism of action and benefits across several consumer health and therapeutic areas



Large Addressable Markets with Unmet needs

- A pipeline of similar exciting and potentially highly valued programs
- Early success with key focused consumer health programs leading to exit opportunities with large strategic partners, existing global amino acid and/or ingredient players



Commercially Proven

- Early commercial success of enterade® and the global partnership with the leading nutritional company, Nestle Health Sciences, validates the market potential of the platform



Experienced Management Team

- Experienced, Market Focused Executives and Managers
- Sector Specific Expertise
- Proven Track Record of Successful exits

An investment of \$25 million provides resources to accelerate and advance key programs for a strong exits



Seasoned Management Team



Stephen J. Gatto, Chairman and CEO

- Prior Chairman and Chief Executive Officer of Myriant Corporation and Chief Executive Officer of BC International Corp
- Has served on numerous presidential, congressional and US DOE/DOA committees
- Appointed by the Clinton and Bush administrations, respectively, to the Biomass Research & Development Technical Advisory Committee



Daniel B. Dennison, PhD, CTO and Board Director

- 25 years senior leadership roles at The Coca-Cola Company, including Vice President and Director of Research and Development and Vice President and Director of Scientific Affairs
- Member of American Association of the Advancement of Science and the Institute of Food Technologies and founding member of the Centers for Disease Control Foundation




Sadasivan Vidyasagar, MD, PhD, CSO and Co-founder

- Assistant Professor in the Department of Radiation Oncology at the University of Florida
- Previously a Wellcome Research Officer at Christian Medical College and Hospital Vellore, Vellore, Tamil Nadu, India, where he studied enteric diseases



John Thomaszewicz, Vice President Operations

- Over 30 years operational services (Myriant Corporation, Siemens, RVSI, Omni)
- Information Technology Expert
- Certified Programme Manager - Siemens



Chester A. Baker, Senior Vice President, Corporate Development

- Over 30 yrs experience with blue chip health care and consumer packaged goods organizations including Procter & Gamble, Abbott Laboratories, and Ocean Spray
- Broad-based global experience as an in-country GM, and leading existing and new business development, insights, and breakthrough innovation around the world



Joseph Del Regno, Chief Marketing Officer

- Former VP of Marketing and GM at Welch's. Over 30 yrs experience in marketing, selling, innovating, and licensing some of the world's most iconic brands, including Pillsbury, Orville Redenbacher's, Samsonite, Sesame Street, and Monopoly
- Significant start-up experience in skin care
- Retail experience for Samsonite, advisorships at Walmart, Target, Walgreens etc, and a Supplier of the Year award from Starbucks



Executive Management Advisors

Michael Chuisano

- Former VP & COO Johnson & Johnson JJDC
- Healthcare Executive with over 30 years experience including business development, venture investing and operating officer experience

Neal Matheson

- Former EVP, Chief Technology Officer (CTO) for the Johnson & Johnson Family of Consumer Companies
- Former EVP, CTO Unilever

Gerard Hoetmer

- Former Chief Executive Officer for CSM
- Former EVP Supply Chain Unilever

Dr. Luba Greenwood, JD

- Strategic Business Development and Corporate Ventures at Google, Verily
- Former Vice President of Global Business Development and Mergers & Acquisitions at Roche



World Class Advisory Board

Henry J. Binder, MD

- Chairman of the EHS Scientific Advisory Board
- Yale School of Medicine Advisory Board and Professor Emeritus of and Senior Research Scientist in Medicine (Digestive Diseases)

Jervoise Andreyev, MD, PhD

- Royal London Hospital
- PhD in molecular biology from the Institute of Cancer Research
- First gastroenterologist appointed specifically to treat the side effects of cancer treatments

Olivier Fontaine, MD, MS, FACP

- Medical Officer for World Health Organization in the Diarrheal Diseases Control Program
- MD, University Paris V (France)

Charles. F. Fuchs, MD, MPH

- Director of Yale Cancer Center
- Physician-in-chief at Smilow Cancer Hospital

Paul Okunieff, MD, CMO and Co-founder

- Chair Radiation Oncology, University of Florida Health
- Previously National Cancer Institute professor of radiation oncology at Harvard Medical School

Dorothy Keefe, PSM MBBS MD FRACP FRCP

- Clinical Ambassador for the Transforming Health initiative in SA
- Professor of Cancer Medicine at the University of Adelaide
- Senior Medical Oncologist at Royal Adelaide Hospital Cancer Centre
- Immediate Past-President of the Multinational Association of Supportive Care in Cancer (MASCC)

Bruce Levy, MD

- Parker B. Francis Professor of Medicine at Harvard Medical School
- Chief, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital

Steven E. Finkelstein, MD, FACRO

- Cancer Center Director, BRCC
- Co-Chair, NRG Immunotherapy Cmte and Chair, SWOG Radiation STG Cmte
- Sr. Director, ASTRO eContouring and Co-Chair, 2018 ACRO Scientific Program Committee
- Editor-in-Chief, Contemporary Radiation Oncology and Editor, ASCO Publications



Proforma P&L – key assumptions



Proforma P&L Summary



Detailed Financial Summary (recap of 2018, detailed 2019 Budget)



OTHER SIDES



Back up



Key Organizational Priorities

PRIORITY	OBJECTIVE	TIMING
Hire Key Personnel	<ul style="list-style-type: none"> Key hires - CFO, VP R&D, VP BD, VP Communication Finalize comprehensive compensation/equity plan 	Q2'19
Finalize NHSc Global Partnership/ Transition	<ul style="list-style-type: none"> Successfully Complete NET Study & Results Q2'19 Complete Transition Activities (Sales/Mktg & Mfg) Q1'19 Close on 2nd License Payment 	Q3'19
Capital Raise	<ul style="list-style-type: none"> Finalize preparations for capital raise \$25 million Update financials, corporate deck, hire Banker 	Q3'19
Establish R&D Center & Staff	<ul style="list-style-type: none"> R&D Center for development work/lab and address key program/product deliverables and critical data Hire 3-5 Scientists to support Pipeline initiatives and manage stage gate process 	Q2'19
Partner Medical Hydration	<ul style="list-style-type: none"> Finalize strategy and plans for MH partnering Progress partner discussions and close global partnership 	Q3'19
Focus on Consumer Health	<ul style="list-style-type: none"> Transition resources out of non-Consumer Health initiatives 	Q2'19



R&D Spend — UF Labs

R&D RESOURCE	Q1	Q2	Q3	Q4	TOTAL
Med HD, Lifestyle, Anti-D	\$50.00	\$50.00	\$50.00	\$50.00	\$200.00
Skin	\$37.50	\$37.50	\$37.50	\$37.50	\$150.00
Cystic Fibrosis & Constipation	\$85.00	\$85.00	\$85.00	\$85.00	\$340.00
Respiratory GSK	\$75.00	\$75.00	\$75.00	\$75.00	\$300.00
Iron Deficiency	\$ -	\$ -	\$ -	\$ -	\$ -
Hemochromatosis	\$37.50	\$37.50	\$ -	\$ -	\$75.00
Tumor	\$ -	\$ -	\$ -	\$ -	\$ -
Total R&D Spend UF Labs	\$285.00	\$285.00	\$247.50	\$247.50	\$1,065.00



PROGRAM AREAS	CATEGORY	TARGET/INDICATIONS	NDA OR IND	PRE-CLINICAL	CLINICAL	COMMERCIAL	PARTNER
Digestive Health	Oncology Patient Care	Dietary management of GI dysfunction associated with cancer treatments	—				Nestle Health Services
	Oncology Patient Care	Chronic diarrhea and dehydration due to complications from Neuroendocrine Tumors and Carcinoid Syndrome	—				
	GI Disease Patient Care	Chronic compromised gut due to GI Diseases incl. Crohns, Colitus and Celiac	—				
	Medical Hydration	Oral rehydration and restoration solutions due to moderate and severe dehydration (illness, or age-related conditions)	—				Army, Sonoma State, Penn State
	Anti-Diarrheal	Natural anti-diarrheal for acute episodic care	✓				JNJ – ICDDR”B Study
	Constipation	Relief of constipation by increasing osmotic activity in the gut by increasing chloride secretion (linked to CF project)	—				
	Gut Health & Wellness	Solutions for microbiome, barrier function and absorption providing optimal function and overall health	—				Path/Gates - Kenya
Personal Care	Complicated Skin Conditions	Dermatologic treatment of Atopic Dermatitis (eczema), Psoriasis	✓				
	Skin Hydration	Topical moisturization and hydration of skin, Anti-Aging	—				
	Wound Healing	Topical treatment to improve acute wound healing and chronic wounds from trauma, ulcers; Herpes	✓				
	Respiratory Care	Chronic asthma and allergy; rhinitis; COPD	—				NIH Grant
	Iron Metabolism	Treatment Iron Deficiency Anemia by expressing DMT-1	—				
	Oral Care	Chronic dry mouth, Mucositis, Mouth Sores	—				
	Eye Care	Hydration to relieve dry eye, allergy symptoms	—				
Therapeutics	Tumor Regression	Anti-tumor activity [anti-cancer (anti-proliferation) activity of amino acids as chemopreventative and therapeutic agent) for esophageal and upper and lower	✓				
	Cystic Fibrosis	Oral treatment for Cystic fibrosis by improving CFTR function and opening the chloride channel	✓				
	Hemochromatosis	Treatment for Iron overload through suppression of DMT-1	✓				



Competitive Landscape – Hydration

COMPANY	TECHNOLOGY	SUMMARY
Pedialyte <i>(Div of Abbott Nutrition)</i>	Glucose based ORS	<ul style="list-style-type: none"> Market leader in pediatric hydration for diarrhea Advanced formula to meet ORS stds Expansion into Adult/Senior Care, Hangover Relief
Drip Drop	Glucose based ORS	<ul style="list-style-type: none"> Hydration powders in child-friendly and better tasting flavors than Pedialyte (target)
Einsof Biohealth	Nano-encapsulated electrolytes	<ul style="list-style-type: none"> Target taste issues with traditional ORS products (salt), and faster absorption
Pantheryx	Combination of protein, amino acids, fats and carbohydrates	<ul style="list-style-type: none"> Nutritional support product, with better taste Anti-diarrheal product (DiaResQ brand)
LiveLeaf	Natural extracts and green tea and bound hydrogen peroxide	<ul style="list-style-type: none"> Anti-diarrheal focused product for fast natural relief of travelers diarrhea (moderate to severe)
Hydrus	Phospholipid delivery (nanosomes) encapsulating electrolytes and water	<ul style="list-style-type: none"> Claim faster and non-glucose based ORS ,in powder and liquid, sold as a dietary supplement. No clinical data.
Kaleido Biosciences	Combination of glycans that have prebiotic	<ul style="list-style-type: none"> Broad digestive health; Anti-diarrheal targeting bacterial related diarrhea; raised funding from Flagship Ventures 2015;
Biomic Sciences	Stabilized lignite extract with water, sales, lithium and traces of AA's	<ul style="list-style-type: none"> Restore Branded product; target gut health and wellness
Axcella	Amino Acid based platform	<ul style="list-style-type: none"> Focus on orphan disease, muscle wasting; strategy is a work in progress; NHSc investment and spun out of Flagship incubator
Sabatini Labs / Whitehead Institute	mTOR pathway by certain amino acids	<ul style="list-style-type: none"> Functional genomics, focused on promoting intestinal stem cell or non-stem cell function



Global Partnership Landscape


EHS is actively building strategic partnerships with global leaders in medical, consumer/lifestyle and nutrition to advance product development, testing and commercialization.



Overall, partnerships represent \$250B potential market opportunity



R&D Resource Plan





EHS Multi-Year R&D Spending

Summary (000's)

DEVELOPMENTAL UNIT	2019	2020	2021	2022	2023
Med Hyd, Lifestyle	\$200	\$100	\$ –	\$ –	\$ –
Cystic Fibrosis & Constipation	\$340	\$1,375	\$3,300	\$ –	\$ –
Respiratory	\$300	\$700	\$500	\$ –	\$ –
Skin Care	\$150	\$640	\$490	\$ –	\$ –
Iron/Deficiency/Overload	\$75	\$1,000	\$1,500	\$ –	\$ –
Total	\$1,065	\$3,815	\$5,790	\$ –	\$ –